Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

• Status: Completed
• Trial end date: 2020-09-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Apremilast; BMS-986165

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Plaque psoriasis for at least 6 months

• Moderate to severe disease

• Candidate for phototherapy or systemic therapy

Exclusion Criteria:

• Other forms of psoriasis

• History of recent infection

• Prior exposure to BMS-986165 or active comparator

Other protocol defined inclusion/exclusion criteria apply